BCM
ERNA icon

Bridgeway Capital Management’s Eterna Therapeutics ERNA Stock Holding History

Bridgeway Capital Management’s Portfolio ERNA Stock Details ERNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2
Closed -$3K – 1397
2022
Q3 		$3K Hold
2
– – ﹤0.01% 1404
2022
Q2 		$7K Sell
2
-16
-89% -$115K ﹤0.01% 1319
2022
Q1 		$282K Buy
+18
New +$342K 0.01% 1097
2021
Q3 		– Sell
-2
Closed -$270K – 1309
2021
Q2 		$270K Hold
2
– – ﹤0.01% 1222
2021
Q1 		$65K Buy
+2
New +$108K ﹤0.01% 1342

Other funds holding ERNA

NW
Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return
CPWM
Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return
Corient Private Wealth
Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Bridgeway Capital Management's ERNA Position: Q4 2022 in Review

Bridgeway Capital Management sold out of Eterna Therapeutics (ERNA) in Q4 2022, closing a stake of 2 shares — an estimated $3K sold.

Bridgeway Capital Management first reported a position in ERNA in Q1 2021 and held it in 5 quarters. The position peaked at $282K in Q1 2022. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

  • Bridgeway Capital Management reported no remaining Eterna Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 2 Eterna Therapeutics shares in Q4 2022, an estimated $3K.
  • Bridgeway Capital Management first reported a position in Eterna Therapeutics in Q1 2021 and held it in 5 quarters.
  • Bridgeway Capital Management's Eterna Therapeutics position peaked at $282K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2022.

Based on Bridgeway Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.